CD79A and cancer: Growing evidences clarify the contribution of B cells to MASH as well as MASH-to-HCC transition, and we have also demonstrated that inflammation-induced immunosuppressive IgA+ B cells dismantle anti-cancer immunity by suppressing cytotoxic CD8+ T lymphocyte (CTL) activation in MASH-driven HCC [17].